Clinical, molecular, and treatment-related predictors of survival in IDH-mutant grade 4 astrocytoma: a single-center cohort study
Journal of Medicine and Palliative Care · 27.03.2026 · 7 (2) · 336-343
DOI: 10.47582/jompac.1864399 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Medicine and Palliative Care, online erschienen am 27.03.2026. Verfasst von Ahmet Ünlü und 1 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Gefördert von: No funding or institutional support was received for this study..
Abstract (Originalsprache)
Aims
Astrocytoma, IDH-mutant, CNS WHO grade 4 represents a biologically distinct subgroup of high-grade gliomas characterized by more favorable outcomes than IDH-wild-type glioblastoma. However, despite the uniform application of glioblastoma-based treatment paradigms, substantial heterogeneity in survival persists, and the clinical, molecular, and treatment-related determinants of outcomes in this entity remain incompletely defined.
Methods
We conducted a retrospective single-center cohort study of adult patients with histologically and molecularly confirmed IDH-mutant grade 4 astrocytomas treated between 2013 and 2024. Clinical, surgical, molecular, and treatment related variables were analyzed for associations with OS and PFS. Survival outcomes were estimated using the Kaplan–Meier method, and prognostic factors were evaluated using univariate and multivariate Cox proportional hazards models. To avoid immortal time bias, adjuvant temozolomide duration was not included in the primary multivariable analyses.
Results
A total of 46 patients were included, with a median follow-up of 19.7 months. The median OS and PFS were 26.0 months (95% CI, 21.4–30.6) and 17.7 months (95% CI, 15.8–19.6), respectively. In multivariable analyses, ECOG performance status, Ki-67 proliferation index, and MGMT promoter methylation status emerged as independent predictors of OS, whereas performance status, extent of surgical resection, and MGMT promoter methylation independently predicted PFS. Completion of 12 cycles of adjuvant temozolomide was associated with improved survival in univariate analyses but was interpreted cautiously due to its time-dependent nature.
Conclusion
Survival heterogeneity in IDH-mutant grade 4 astrocytomas reflects the combined influence of tumor biology and host-related factors, rather than the molecular subtype alone. Integrating functional performance, proliferative activity, and MGMT promoter status may enhance risk stratification and inform individualized clinical decision-making for this distinct glioma subtype.
Förderung
- No funding or institutional support was received for this study.
Zitieren
APA
Ünlü, A., & Aydın, A. A. (2026). Clinical, molecular, and treatment-related predictors of survival in IDH-mutant grade 4 astrocytoma: a single-center cohort study. Journal of Medicine and Palliative Care, 7(2), 336-343. https://doi.org/10.47582/jompac.1864399
Vancouver
Ünlü A, Aydın AA. Clinical, molecular, and treatment-related predictors of survival in IDH-mutant grade 4 astrocytoma: a single-center cohort study. Journal of Medicine and Palliative Care. 2026;7(2):336-343. doi:10.47582/jompac.1864399
BibTeX
@article{nl2026,
author = {Ünlü, Ahmet and Aydın, Asım Armağan},
title = {Clinical, molecular, and treatment-related predictors of survival in IDH-mutant grade 4 astrocytoma: a single-center cohort study},
journal = {Journal of Medicine and Palliative Care},
year = {2026},
volume = {7},
number = {2},
pages = {336--343},
doi = {10.47582/jompac.1864399}
}
EUVIMED